Heart failure has been reported as a rare side effect of bevacizumab, a chemotherapeutic agent, used in
the treatment of breast cancer. However, reversible left ventricular systolic dysfunction with a pattern
similar to stress-induced cardiomyopathy has not been reported. The etiopathogenesis of stress-induced
cardiomyopathy is poorly understood. Given this uncertainty, we should always look out for other
potential offenders causing similar presentation, rather than label all of them as stress-induced.
Key words: Bevacizumab,Heart failure,Stress-induced cardiomyopathy
|
